|
| 37496441 | <i>PVT1</i> interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma. | Haematologica | 2024 |
| 36309559 | An MDM2 degrader for treatment of acute leukemias. | Leukemia | 2023 |
| 38019706 | Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer. | J Med Chem | 2023 |
| 37624737 | Chemical Epigenetic Regulation of Adeno-Associated Virus Delivered Transgenes. | Hum Gene Ther | 2023 |
| 37555591 | De Novo Design of κ-Opioid Receptor Antagonists Using a Generative Deep-Learning Framework. | J Chem Inf Model | 2023 |
| 38002340 | Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists. | Biomolecules | 2023 |
| 38055802 | USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice. | Sci Transl Med | 2023 |
| 37774414 | Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2. | J Am Chem Soc | 2023 |
| 37537299 | WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. | Nat Cancer | 2023 |
| 37354907 | Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization. | Cell Chem Biol | 2023 |
| 37391487 | Correction: An MDM2 degrader for treatment of acute leukemias. | Leukemia | 2023 |
| 37291217 | Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1. | Cell Death Differ | 2023 |
| 37314393 | Chemically induced degradation of epigenetic targets. | Chem Soc Rev | 2023 |
| 37379717 | Recent advances in developing degraders & inhibitors of lysine methyltransferases. | Curr Opin Chem Biol | 2023 |
| 37339625 | Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. | Cell Host Microbe | 2023 |
| 37141574 | Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins. | J Am Chem Soc | 2023 |
| 37169612 | Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. | Sci Bull (Beijing) | 2023 |
| 37233993 | A novel mechanism regulating pyroptosis-induced fibrosis in endometriosis via lnc-MALAT1/miR-141-3p/NLRP3 pathwayâ¿ . | Biol Reprod | 2023 |
| 37365684 | Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53. | J Am Chem Soc | 2023 |
| 37001386 | Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. | Int Immunopharmacol | 2023 |
| 37398396 | Novel small molecules inhibit proteotoxicity and inflammation: Mechanistic and therapeutic implications for Alzheimer's Disease, healthspan and lifespan- Aging as a consequence of glycolysis. | bioRxiv | 2023 |
| 37162828 | De Novo Design of κ-Opioid Receptor Antagonists Using a Generative Deep Learning Framework. | bioRxiv | 2023 |
| 36747009 | Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. | Oncogene | 2023 |
| 36538511 | Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. | J Med Chem | 2023 |
| 36737841 | Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy. | Adv Sci (Weinh) | 2023 |
| 36899200 | Baicalein Inhibits the Growth of Transplanted Esophageal Cancer in Mice and the Effect on the Expression of PAK4. | Bull Exp Biol Med | 2023 |
| 36793594 | MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicing. | Front Oncol | 2023 |
| 34469831 | A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. | Cell Chem Biol | 2022 |
| 35710782 | Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia. | Cell Death Dis | 2022 |
| 35675209 | Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. | J Med Chem | 2022 |
| 35837138 | Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2. | ACS Pharmacol Transl Sci | 2022 |
| 35835867 | Inactive and active state structures template selective tools for the human 5-HT<sub>5A</sub> receptor. | Nat Struct Mol Biol | 2022 |
| 35578032 | PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. | Nat Chem Biol | 2022 |
| 35763668 | Discovery of the First-in-Class G9a/GLP Covalent Inhibitors. | J Med Chem | 2022 |
| 35786952 | TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors. | J Am Chem Soc | 2022 |
| 35525905 | Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. | Oncogene | 2022 |
| 36448571 | Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets. | J Am Chem Soc | 2022 |
| 36041010 | The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. | Sci Signal | 2022 |
| 36040262 | Crystal structure of SARS-CoV-2 nsp10-nsp16 in complex with small molecule inhibitors, SS148 and WZ16. | Protein Sci | 2022 |
| 36300627 | A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation. | Nucleic Acids Res | 2022 |
| 35895319 | Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos. | J Med Chem | 2022 |
| 36197750 | Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. | J Med Chem | 2022 |
| 35217626 | A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia. | Proc Natl Acad Sci U S A | 2022 |
| 35119851 | Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies. | J Med Chem | 2022 |
| 35210568 | EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. | Nat Cell Biol | 2022 |
| 33469207 | Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. | Nat Rev Drug Discov | 2021 |
| 33594072 | ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. | Nat Commun | 2021 |
| 33619486 | Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors. | bioRxiv | 2021 |
| 33591753 | A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6. | J Med Chem | 2021 |
| 33750924 | NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. | Commun Biol | 2021 |